Epigenomics of human colon cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 693, Issue 1-2, 2010, Pages 53-60

  Carmona, F Javier ^a   Esteller, Manel ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Colon cancer; DNA methylation; Epigenomics; Genome wide

Indexed keywords

CADHERIN; CYCLIN A1; CYCLOOXYGENASE 2; DEATH ASSOCIATED PROTEIN KINASE; DICKKOPF 1 PROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; FOLLISTATIN; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETINOL BINDING PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; SODIUM GLUCOSE COTRANSPORTER 8; SOMATOMEDIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; UNCLASSIFIED DRUG;

CANCER GENETICS; CARCINOGENESIS; COLON CANCER; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENOMICS; HUMAN; IMMUNOPRECIPITATION; MOLECULAR HYBRIDIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; REVIEW; TUMOR CLASSIFICATION;

COLONIC NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS;

EID: 78049443505     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.07.007     Document Type: Review

References (82)

1. Esteller M. Epigenetics in cancer. The New England Journal of Medicine 2008, 358(11):1148-1159.
2. Fraga M.F., Ballestar E., Villar-Garea A., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 2005, 37(4):391-400.
3. Seligson D.B., Horvath S., Shi T., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435(7046):1262-1266.
4. Trang P., Weidhaas J.B., Slack F.J. MicroRNAs as potential cancer therapeutics. Oncogene 2008, 27(Suppl. 2):S52-S57.
5. Wagner K.J., Cooper W.N., Grundy R.G., et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002, 21(47):7277-7282.
6. Alazzouzi H., Davalos V., Kokko A., et al. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Research 2005, 65(22):10170-10173.
7. Gonzalez-Zulueta M., Bender C.M., Yang A.S., et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Research 1995, 55(20):4531-4535.
8. Goel A., Arnold C.N., Niedzwiecki D., et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Research 2004, 64(9):3014-3021.
9. Esteller M., Fraga M.F., Guo M., et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Human Molecular Genetics 2001, 10(26):3001-3007.
10. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301(5895):89-92.
11. Chan A.O., Broaddus R.R., Houlihan P.S., Issa J.P., Hamilton S.R., Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. The American Journal of Pathology 2002, 160(5):1823-1830.
12. Chan A.O., Issa J.P., Morris J.S., Hamilton S.R., Rashid A. Concordant CpG island methylation in hyperplastic polyposis. The American Journal of Pathology 2002, 160(2):529-536.
13. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299(5613):1753-1755.
14. Woodson K., Flood A., Green L., et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. Journal of the National Cancer Institute 2004, 96(5):407-410.
15. Bock C., Paulsen M., Tierling S., Mikeska T., Lengauer T., Walter J. CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats, and predicted DNA structure. PLoS Genetics 2006, 2(3):e26.
16. Feltus F.A., Lee E.K., Costello J.F., Plass C., Vertino P.M. DNA motifs associated with aberrant CpG island methylation. Genomics 2006, 87(5):572-579.
17. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(15):8681-8686.
18. Yamashita K., Dai T., Dai Y., Yamamoto F., Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003, 4(2):121-131.
19. Anacleto C., Leopoldino A.M., Rossi B., et al. Colorectal cancer " methylator phenotype": fact or artifact?. Neoplasia (New York, NY) 2005, 7(4):331-335.
20. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 2003, 349(21):2042-2054.
21. Toyooka S., Toyooka K.O., Harada K., et al. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Research 2002, 62(12):3382-3386.
22. Luo L., Chen W.D., Pretlow T.P. CpG island methylation in aberrant crypt foci and cancers from the same patients. International Journal of Cancer 2005, 115(5):747-751.
23. Mittag F., Kuester D., Vieth M., et al. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Letters 2006, 240(1):69-75.
24. Cruz-Correa M., Cui H., Giardiello F.M., et al. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004, 126(4):964-970.
25. Ebert M.P., Mooney S.H., Tonnes-Priddy L., et al. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia (New York, NY) 2005, 7(8):771-778.
26. Lee B.B., Lee E.J., Jung E.H., et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clinical Cancer Research 2009, 15(19):6185-6191.
27. Jacinto F.V., Ballestar E., Ropero S., Esteller M. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Research 2007, 67(24):11481-11486.
28. Paz M.F., Wei S., Cigudosa J.C., et al. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Human Molecular Genetics 2003, 12(17):2209-2219.
29. Suzuki H., Watkins D.N., Jair K.W., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genetics 2004, 36(4):417-422.
30. Esteller M., Sparks A., Toyota M., et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Research 2000, 60(16):4366-4371.
31. Toyota M., Shen L., Ohe-Toyota M., Hamilton S.R., Sinicrope F.A., Issa J.P. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Research 2000, 60(15):4044-4048.
32. Xu X.L., Yu J., Zhang H.Y., et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World Journal of Gastroenterology 2004, 10(23):3441-3454.
33. Hellebrekers D.M., Lentjes M.H., van den Bosch S.M., et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clinical Cancer Research 2009, 15(12):3990-3997.
34. Wales M.M., Biel M.A., el Deiry W., et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine 1995, 1(6):570-577.
35. Ricciardiello L., Goel A., Mantovani V., et al. Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Research 2003, 63(4):787-792.
36. Lee S., Hwang K.S., Lee H.J., Kim J.S., Kang G.H. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Laboratory Investigation: A Journal of Technical Methods and Pathology 2004, 84(7):884-893.
37. Yamamoto H., Min Y., Itoh F., et al. Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability. Genes, Chromosomes & Cancer 2002, 33(3):322-325.
38. Rojas A., Meherem S., Kim Y.H., et al. The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. International Journal of Cancer 2008, 123(1):14-21.
39. Aguilera O., Fraga M.F., Ballestar E., et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006, 25(29):4116-4121.
40. Moinova H.R., Chen W.D., Shen L., et al. HLTF gene silencing in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(7):4562-4567.
41. Lujambio A., Calin G.A., Villanueva A., et al. A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(36):13556-13561.
42. Li H., Myeroff L., Smiraglia D., et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(14):8412-8417.
43. Akiyama Y., Watkins N., Suzuki H., et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Molecular and Cellular Biology 2003, 23(23):8429-8439.
44. Lewin J., Plum A., Hildmann T., et al. Comparative DNA methylation analysis in normal and tumour tissues and in cancer cell lines using differential methylation hybridisation. The International Journal of Biochemistry & Cell Biology 2007, 39(7-8):1539-1550.
45. Frigola J., Sole X., Paz M.F., et al. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Human Molecular Genetics 2005, 14(2):319-326.
46. Rhee I., Bachman K.E., Park B.H., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416(6880):552-556.
47. Lujambio A., Ropero S., Ballestar E., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Research 2007, 67(4):1424-1429.
48. Lind G.E., Kleivi K., Meling G.I., et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cellular Oncology 2006, 28(5-6):259-272.
49. Suzuki H., Gabrielson E., Chen W., et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics 2002, 31(2):141-149.
50. Gargiulo G., Minucci S. Epigenomic profiling of cancer cells. The International Journal of Biochemistry & Cell Biology 2009, 41(1):127-135.
51. Yamashita K., Park H.L., Kim M.S., et al. PGP9.5 methylation in diffuse-type gastric cancer. Cancer Research 2006, 66(7):3921-3927.
52. Yamashita K., Upadhyay S., Osada M., et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002, 2(6):485-495.
53. Brena R.M., Costello J.F. Genome-epigenome interactions in cancer. Human Molecular Genetics 2007, 16(Spec No. 1):R96-R105.
54. Weber M., Davies J.J., Wittig D., et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics 2005, 37(8):853-862.
55. Keshet I., Schlesinger Y., Farkash S., et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nature Genetics 2006, 38(2):149-153.
56. Adorjan P., Distler J., Lipscher E., et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Research 2002, 30(5):e21.
57. Down T.A., Rakyan V.K., Turner D.J., et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nature Biotechnology 2008, 26(7):779-785.
58. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews 2007, 8(4):286-298.
59. Frommer M., McDonald L.E., Millar D.S., et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(5):1827-1831.
60. Clark S.J., Harrison J., Paul C.L., Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Research 1994, 22(15):2990-2997.
61. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(18):9821-9826.
62. Ying J., Li H., Yu J., et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clinical Cancer Research 2008, 14(1):55-61.
63. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nature Reviews: Cancer 2006, 6(2):107-116.
64. van Rietschoten J.G., Gal-Yam E.N., Jeong S., Cortez C.C., Verweij C.L., Jones P.A. Epigenetic regulation and nucleosome positioning in the human TATA-less IL-1 alpha promoter. Genes and Immunity 2008, 9(7):582-590.
65. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Research 2001, 61(8):3225-3229.
66. Model F., Osborn N., Ahlquist D., et al. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Molecular Cancer Research 2007, 5(2):153-163.
67. Martinez R., Schackert G., Yaya-Tur R., Rojas-Marcos I., Herman J.G., Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. Journal of Neuro-Oncology 2007, 83(1):91-93.
68. Worm J., Aggerholm A., Guldberg P. In-tube DNA methylation profiling by fluorescence melting curve analysis. Clinical Chemistry 2001, 47(7):1183-1189.
69. Candiloro I.L., Mikeska T., Hokland P., Dobrovic A. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics & Chromatin 2008, 1(1):7.
70. Trinh B.N., Long T.I., Laird P.W. DNA methylation analysis by MethyLight technology. Methods (San Diego, Calif.) 2001, 25(4):456-462.
71. Kawasaki T., Ohnishi M., Nosho K., et al. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Modern Pathology 2008, 21(3):245-255.
72. Oberwalder M., Zitt M., Wontner C., et al. SFRP2 methylation in fecal DNA - a marker for colorectal polyps. International Journal of Colorectal Disease 2008, 23(1):15-19.
73. Wang D.R., Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World Journal of Gastroenterology 2008, 14(4):524-531.
74. Bibikova M., Lin Z., Zhou L., et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Research 2006, 16(3):383-393.
75. Rauch T.A., Pfeifer G.P. The MIRA method for DNA methylation analysis. Methods in Molecular Biology (Clifton, NJ) 2009, 507:65-75.
76. Oda M., Greally J.M. The HELP assay. Methods in Molecular Biology (Clifton, NJ) 2009, 507:77-87.
77. Futscher B.W., Oshiro M.M., Wozniak R.J., et al. Role for DNA methylation in the control of cell type specific maspin expression. Nature Genetics 2002, 31(2):175-179.
78. Eckhardt F., Lewin J., Cortese R., et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nature Genetics 2006, 38(12):1378-1385.
79. Irizarry R.A., Ladd-Acosta C., Wen B., et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nature Genetics 2009, 41(2):178-186.
80. von Bubnoff A. Next-generation sequencing: the race is on. Cell 2008, 132(5):721-723.
81. Fan J.B., Chee M.S., Gunderson K.L. Highly parallel genomic assays. Nature Review: Genetics 2006, 7(8):632-644.
82. Clarke J., Wu H.C., Jayasinghe L., Patel A., Reid S., Bayley H. Continuous base identification for single-molecule nanopore DNA sequencing. Nature Nanotechnology 2009, 4(4):265-270.